Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470540 | 1.00 | KMT2A (0.45) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL1000962 | 1.00 | KMT2A (0.45) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL1745934 | 1.00 | KMT2A (0.45) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL31146900 | 1.00 | KMT2A (0.45) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL3367289 | 1.00 | KMT2A (0.45) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL14416300 | 0.93 | KMT2A (0.42) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL13183250 | 0.92 | KMT2A (0.42) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL30558303 | 0.92 | KMT2A (0.42) | KMT2AMEN1CASP3NPC1RAB9A | |
| SCHEMBL12873284 | 0.92 | LMNA (0.46) | KMT2AMEN1CASP3MDM2FABP5 | |
| SCHEMBL12555211 | 0.92 | KMT2A (0.47) | KMT2AMEN1CASP3MDM2FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104593-A1 | FRAGMENT BASED SYNTHESIS OF PEPTIDES SUCH AS LL37 | NEUROINNOVATECH APS (DK) | 2026-05-21 | — | — | WO | claimed |
| CN-121574188-A | Application of donkey-source bioactive peptide and its derivative in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-121574187-A | Application of donkey-source bioactive peptide and derivative thereof in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| WO-2025264177-A1 | METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2025-12-26 | — | — | WO | claimed |
| US-20250289845-A1 | SUBSTRATE FOR SOLID-PHASE ORGANIC SYNTHESIS AND SOLID-PHASE ORGANIC SYNTHESIS METHOD USING THE SAME | KANG SUNG KOO (KR) | 2025-09-18 | — | — | US | claimed |
| CN-120081910-A | GLP-1, GIP and GCG tri-receptor co-agonist and application thereof | 惠升生物制药股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118459550-B | Small molecular compound and preparation method and application thereof | 广东医科大学附属医院 | 2024-10-29 | — | — | CN | claimed |
| CN-118005766-B | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-111944040-B | Solid phase synthesis method of abamectin | 海南中和药业股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-116217672-A | Pure gonadotropin releasing hormone antagonist cetrorelix | 海南中和药业股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-116120403-A | Method for preparing Tirzepatide through solid phase | 成都普康唯新生物科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115536739-B | Preparation method of GLP-1 receptor and GCG receptor co-agonist polypeptide derivative | 北京惠之衡生物科技有限公司 | 2023-04-14 | — | — | CN | claimed |
| EP-4161553-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VectivBio AG (CH) | 2023-04-12 | — | — | EP | claimed |
| US-11571456-B2 | Process for the linear synthesis of gram-positive class II bacteriocins and compositions and uses thereof | UNIVERSITé LAVAL (CA) | 2023-02-07 | — | — | US | claimed |
| CN-115536739-A | Preparation method of GLP-1 receptor and GCG receptor co-agonist polypeptide derivative | 北京惠之衡生物科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| WO-2022109456-A1 | METHODS OF MAKING AND USING PLATFORMS FOR PEPTIDE SYNTHESIS AND COMPOSITIONS THEREOF | LEE FRANCIS (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114366803-A | Medicine for treating bacterial endophthalmitis and preparation method thereof | 吉林大学 | 2022-04-19 | — | — | CN | claimed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571456-B2 | Process for the linear synthesis of gram-positive class II bacteriocins and compositions and uses thereof | PSAP, SBDS, MRPL21 | KMT2A 4368/4885MEN1 3280/4885CASP3 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.